The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...

Shareholders of Pfizer may learn more about this investigation by contacting Berger Montague: Radha Raghavan at rraghavan@bm.net or (332) 271-8908, or Andrew Abramowitz at aabramowitz@bm.net or (215) ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

Shares of Merck and Pfizer are way down from their previous peaks. Merck's lead drug, Keytruda, grew sales by 19% last year, but its era of patent-protected exclusivity is approaching its end.

That mission is getting a big boost from the late John Mitchell, a longtime supporter and Pfizer Global Manufacturing executive. “… then he goes and has this, certainly, very celebrated ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past ...

At close: 7 February at 5:35:56 pm GMT+1 ...

At close: 7 February at 3:48:43 pm GMT+5:30 ...